All In Biotech

Drug Trial Radar · NCT07027072

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

114

Planned (sponsor's estimate)

Start

Aug 6, 2025

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
NeuroBiogen Co., LtdIndustry
Sponsor type
Industry
First posted
Jun 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease. Based on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI/mild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group). The objectives of the study are as follows: 1. Efficacy Objectives: Efficacy will be evaluated through changes in cognitive function, self-management, and daily living activities before and after administration of KDS2010. Biomarker analysis in plasma and in cerebrospinal fluid (CSF; optional) will also be conducted to explore treatment efficacy. 2. Safety Objectives: The safety and tolerability will be evaluated after administration of KDS2010. 3. Exploratory Objectives: The efficacy of Treatment Groups 1 and 2 compared to the Control group will be explored through cognitive endpoints (the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and the Mini-Mental State Examination (MMSE)), stratified by demographic information, tauopathy, and ApoE4 genes. Based on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at two dose levels: 60 mg and 120 mg.

Conditions

  • Mild Cognitive Impairment (MCI)
  • Mild Dementia
  • Alzheimer's Disease

Interventions

  • KDS2010Drug

    KDS2010 will be administered orally once daily, two tablets per day, for 24 weeks. Dosage will be either 60 mg or 120 mg depending on the assigned group.

  • PlaceboDrug

    Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, two tablets per day, for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scoreTime frame: Screening (-8 Week~), Week 4, Week 8, Week 12, Week 24, Week 26
  2. Time to ≥0.5-point increase in CDR-SBTime frame: Up to Week 26
  3. Change from Baseline in Mini-Mental State Examination (MMSE) scoreTime frame: Screening (-8 Week~), Week 12, Week 24, Week 26
  4. Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) scoreTime frame: Screening (-8 Week~), Week 12, Week 24, Week 26
  5. Change from Baseline in Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q-SV) scoreTime frame: Screening (-8 Week~), Week 12, Week 24

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Chonnam National Unversity Hospital

    Gwangju, Gwangju, South Korea · Recruiting

  • Hanyang University Guri Hospital

    Guri-si, Gyeonggi-do, South Korea · Recruiting

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, Incheon, South Korea · Recruiting

  • Hanyang University Seoul Hospital

    Seoul, Seoul, South Korea · Recruiting

  • Konkuk University Medical Center

    Seoul, Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.